Trulieve Reports Q3 2026 Revenue Growth and Expansion Success in Georgia
Trulieve Cannabis Corp. (TRLV) reported third-quarter results featuring $230.2 million in revenue, a 4% increase year-over-year. The company's performance was bolstered by significant growth in the Georgia medical market following program expansion and product launches, which led to a sevenfold increase in traffic and an 80% rise in patient enrollment since the start of 2026. Operational efficiencies contributed to a gross margin of 64.3% and adjusted EBITDA of $89.2 million. Management highlighted the positive impact of federal rescheduling, which facilitated DEA registration and relieved the company from the 280E tax burden. While a net loss is anticipated for Q4 due to non-cash purchase accounting adjustments related to Harvest deconsolidation, the company maintains strong liquidity with $326.7 million in cash.
Tickers: $TRLV
Topics: Adjusted EPS Cannabis Industry EBITDA Florida Sales Georgia Expansion Gross Margin Revenue Growth